Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

ly there is no marketed treatment for DGF; when DGF is diagnosed the patient is supported with dialysis and other supportive care.

The investigational drug candidate QPI-1002 is a siRNA designed to temporarily inhibit the expression of the pro-apoptotic gene, p53. This siRNA is based on Quark's proprietary, patented therapeutic concept of temporarily inhibiting the expression of p53 to protect normal cells from acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from Alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. QPI-1007, which is a siRNA that utilizes a novel siRNA structure developed by Quark and is being evaluated in advanced IND-e
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
(Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Forces of Change Reshaping Corporate Libraries & Information Services 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
(Date:7/28/2014)... A common inflammatory muscle disorder that causes pain ... risk for heart attack and stroke, new ... patients with polymyalgia rheumatica are more likely to ... blood vessels. Doctors should carefully manage the vascular ... reduce their risk for complications, the study authors ...
(Date:7/28/2014)... A new study, published in the July, 2014, ... Cancer Institute by Northwestern Medicine researchers, sheds ... growing popularity of endoscopic resection in the treatment ... the more traditional surgical resection, while more invasive, ... five-year survival rate for patients than endoscopic resection, ...
(Date:7/28/2014)... Jose, CA (PRWEB) July 28, 2014 ... family life Americans face today, BlogHer, The Center for ... to launch “Make Life Work,” a campaign to raise ... by families across the U.S. The joint initiative was ... Stacy Morrison, Editor-in-Chief, BlogHer; Judith Warner, Senior Fellow, The ...
(Date:7/28/2014)... 2014 The website, which is hosted ... industry, went live in January 2014. The honor recognizes ... of excellence that comprise the web’s most professional work. ... , “What pleases me the most is that we ... categories,” said Joshua Snow, web manager, Abington Health. “We ...
(Date:7/28/2014)... Synergy Business Solutions announced today it was chosen ... list of top 100 value added resellers (VAR) of ... is the eighth year since 2006 that Synergy has ... success in terms of revenue, growth, and accounting software ... to be counted among such a reputable list of ...
Breaking Medicine News(10 mins):Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 2Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 3Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 4Health News:“Make Life Work” Campaign Launches to Address the Needs of Today's Working Families & Promote Realistic Solution 5Health News:Abington Health Website Named Best in Class 2Health News:Synergy Business Solutions Selected to Top 100 VAR List for Eighth Year by Accounting Today 2Health News:Synergy Business Solutions Selected to Top 100 VAR List for Eighth Year by Accounting Today 3
... ... of the myESMO Professional Networking Community, an innovative online platform that offers society members ... ... European Society for Medical Oncology is today pleased to announce the launch of ...
... AWF calls on Gov. Parkinson to condemn and abandon such practices ... Alliance for Worker Freedom (AWF) calls on Kansas Governor Mark Parkinson ... resources and taxpayer money to obtain personal contact information of healthcare ... Kansas. , , Letters obtained by AWF, printed ...
... , SHENZHEN, China, Sept. 14 /PRNewswire-FirstCall/ - HTDS ... following update to its shareholders and followers on the ... subsidiary and other general business matters. , At the ... of Influenza A (H1N1) Vaccine (Split Virion). The company ...
... A popular stomach-acid reducer used to prevent stress ... increases the risk of those patients contracting pneumonia threefold, ... Medicine. Hospital-acquired pneumonia is the leading cause of ... stays by an average of seven to nine days, ...
... , LAS VEGAS, Sept. 14 EQ Labs, Inc. ... the Company held its first public stockholders, meeting at its headquarters ... of the Board and CEO presiding. The Board of Directors ... recommendations of the Board and the resolutions placed before the shareholders ...
... Sept. 14 Tupperware Brands Corporation,s highly successful Chain of ... to celebrate the importance of female friendship and the rewards that ... with organizations in local markets around the world who work to ... , , On September 17, 2009 ...
Cached Medicine News:Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 2Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 3Health News:ESMO Online Innovation Helps the Oncology Community Share Knowledge and Enhance Practice 4Health News:Kansas Departments Use Taxpayer Money and State Resources to Collect Healthcare Workers' Names for the SEIU 2Health News:Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production 2Health News:Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production 3Health News:Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production 4Health News:Popular stomach acid reducer triples risk of developing pneumonia 2Health News:EQLB Releases Letter to Shareholders 2Health News:EQLB Releases Letter to Shareholders 3Health News:BeautiControl(R) Encompasses Tupperware Brands Global Women's Initiative: Chain of Confidence(R) 2
The Advance Unicompartmental Knee System is designed with bone conserving femoral and tibial components that provide reproducible results within a minimal incision. Uni metal backed tibial component....
...
...
... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
Medicine Products: